In journalism and media industry for more than twenty years, worked for a number of media companies. Business editing, research and PR specialist. Covering industry and science news for Ilesol Pharmaceuticals.
A study published in La Clinica terapeutica on February 9, 2022, found that a new multitasking natural drug based on CBD and melatonin could be competitive with classic hypnotic synthetic drugs in insomnia treatment.
In this spontaneous, anecdotal, retrospective, compassionate-use, observational, open-label study, 20 patients aged 43-96 years were recruited to the Second Opinion Medical Consulting Network in Modena, Italy.
The Second Opinion Medical Network is a consultation referral web and medical office system recruiting a wide panel of real-time available specialists, to whom any patient aﬀected by any disease or syndrome and not satisfied with the diagnosis or therapy can apply for an individual clinical audit.
The patients suffering from sleep disorders and anxiety were instructed to take 20 drops of the new natural multitasking liquid containing 2.5 mg of CBD and 1,5 mg of melatonin sublingually overnight for three months of treatment.
Melatonin, often referred to as the sleep hormone, is produced primarily in the pineal gland but also in lymphocytes, bone marrow, skin, gut retina, testis, spermatozoa, and ovaries. Melatonin’s antioxidant activity benefits the brain network, restoring the biological clock functions. CBD reduces chronic pain perception, helps to complete neuromuscular relaxation, and relieves anxiety, fulfilling a very balanced sensation of well-being during sleep. The two natural compounds were combined in the same liquid to address the most common neuropsychological and physical distressing symptoms disturbing regular sleep and causing multiple awakenings.
The distressing symptoms included a variety of conditions such as anxiety, chronic pain, arthritis, depression, hypertension, urinary frequency, and restless legs.
After three months, all the patients completed the trial with a reduction in mood alterations, including anxiety, panic, paranoia, and depression, reduction in pain, and good general health perceptions. There was an improvement in physical symptoms and mood disorders that affected sleep. Sleep improved for all the recruited patients, and they were still satisfied 30-60 days after the end of the trial.
The partial or total symptoms’ remission was recorded in chronic pain relapsing nighttime due to the resting body position, pressure upon joints and bone, involuntary movements; frequent micturition due to prostate enlargement or prostatitis, hyperactive bladder, detrusor instability, anxiety with nightmares and arms and legs involuntary movement and speech; as well as disturbing bowel movements, reflux, and bloating, with or without inflammatory bowel disease (IBD).
There was a remarkable continuity and quality of the sleeping time that restored the patients with energy and daily activity feedback the morning after. Following these results, the authors of the study conclude that physicians could consider the formula CBD (2,5 mg) and melatonin (1,5 mg) as competitive with the classic hypnotic synthetic drugs.